Cocrystal Pharma, Inc. (NASDAQ:COCP) Short Interest Update

Posted by Stanley Muller on May 30th, 2026

Cocrystal Pharma, Inc. (NASDAQ:COCP – Get Free Report) saw a large decrease in short interest in the month of May. As of May 15th, there was short interest totaling 192,682 shares, a decrease of 67.1% from the April 30th total of 586,422 shares. Based on an average daily volume of 138,014 shares, the days-to-cover ratio is currently 1.4 days. Approximately 1.9% of the company’s shares are sold short.

Hedge Funds Weigh In On Cocrystal Pharma

An institutional investor recently bought a new position in Cocrystal Pharma stock. T3 Companies LLC acquired a new stake in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 52,300 shares of the company’s stock, valued at approximately $51,000. T3 Companies LLC owned 0.38% of Cocrystal Pharma as of its most recent SEC filing. Institutional investors and hedge funds own 6.72% of the company’s stock.

Cocrystal Pharma Price Performance

Shares of NASDAQ:COCP traded down $0.01 during trading on Friday, reaching $1.12. 101,603 shares of the company were exchanged, compared to its average volume of 130,481. The firm has a market capitalization of $15.44 million, a PE ratio of -1.53 and a beta of 1.50. The business’s fifty day simple moving average is $1.29 and its 200-day simple moving average is $1.11. Cocrystal Pharma has a 12-month low of $0.86 and a 12-month high of $2.67.

Cocrystal Pharma (NASDAQ:COCP – Get Free Report) last issued its earnings results on Friday, May 15th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The firm had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.23 million. On average, sell-side analysts anticipate that Cocrystal Pharma will post -0.67 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered shares of Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 22nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $6.00.

Check Out Our Latest Stock Report on COCP

Cocrystal Pharma Company Profile

(Get Free Report)

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.